Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $78.2252W HIGH $118.01
Volume
2.71 K
Value Traded
37.75 M
Short % Float
7.95%
+0.86%Week
+0.21%1 Month
-22.48%3 Month
-30.52%6 Month
+97.04%5 Year
+1,403.85%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.83 B
EPS (TTM)
2.87
P/E Ratio
27.73
Ent. Value
1.45 B
Total Shares
22.87 M
Float Shares
21.29 M
Insiders
6.91%
Institutions
100.81%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
LMAT Catalyst Timeline
Dated clinical, regulatory and corporate events for LeMaitre Vascular, Inc.
Past FDA Catalysts and PDUFA Decisions
How LMAT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
LeMaitre Vascular, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every LMAT program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Roush John ADirector | Option | 3,444 7,386 held | $48.60 | 09/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LMAT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in LMAT for Q2 2026. | ||||
LMAT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LMAT ranks across every disease it competes in
Competitive Position is a premium feature
See how LMAT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLMAT News
LMATLeMaitre to Participate at Upcoming Investor Conferences in September
LeMaitre Vascular, Inc. will participate in three investor conferences in September 2026. CFO Dorian LeBlanc will engage in Fireside Chats at the Wells Fargo and Morgan Stanley conferences, as well as at the Barrington Research Virtual Fall Investment Conference. These events aim to strengthen investor relationships and showcase the company's offerings in vascular disease treatment.
Read more →LMATLeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
LeMaitre Vascular, Inc. will hold investor meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 11, 2026. This participation underscores the company's commitment to engaging with investors and highlights its role in the vascular health sector. LeMaitre specializes in devices and services for treating peripheral vascular disease.
Read more →LMAT▼ -25.3%on this newsshared move
LeMaitre Q2 2026 Financial Results
LeMaitre Vascular, Inc. reported strong Q2 2026 financial results, with a 10% increase in sales and a gross margin of 72.1%. The company's Artegraft product saw a significant sales increase of 34%, contributing to overall growth. However, catheter sales were down 11% due to prior overstocking issues. The company announced a quarterly dividend of $0.25 per share and has a robust cash position of $376.2 million.
Read more →LMATLeMaitre Will Announce Second Quarter 2026 Earnings Results on August 4, 2026
LeMaitre Vascular, Inc. has announced that it will release its second quarter 2026 financial results on August 4, 2026, after market close. A conference call is scheduled for the same day at 5:00 PM EDT to discuss the results and company outlook. This reflects the company's ongoing commitment to transparency and stakeholder engagement.
Read more →LMATLeMaitre to Participate at Upcoming Investor Conferences in June
LeMaitre Vascular, Inc. will participate in two investor conferences in June 2026. The Jefferies Global Healthcare Conference is scheduled for June 3, and the Goldman Sachs Annual Global Healthcare Conference will take place on June 10. These events will provide management with opportunities to engage with investors and discuss the company's developments.
Read more →LMATLeMaitre to Present at the Bank of America Healthcare Conference
LeMaitre Vascular, Inc. will present at the Bank of America Healthcare Conference on May 13, 2026, at 5:15 PM PT. The company specializes in devices and services for peripheral vascular disease, impacting over 200 million people globally. This presentation highlights their commitment to engaging with the healthcare community.
Read more →LMATLeMaitre Q1 2026 Financial Results BURLINGTON, MA, May 5, 2026 - LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today
LeMaitre Vascular, Inc. announced strong financial results for Q1 2026, with a reported revenue growth and record sales in multiple product categories. The company achieved a gross margin of 72.7%, an increase attributed to higher pricing and manufacturing efficiencies. Full-year guidance was optimistic, anticipating 12% sales growth and a 26% increase in adjusted EPS. Additionally, a quarterly dividend of $0.25/share was declared, underscoring the company's commitment to shareholder returns.
Read more →LMATLeMaitre Q1 2026 Financial Results
LeMaitre Vascular, Inc. reported strong Q1 2026 financial results with sales of $66.6 million, an 11% increase from the previous year. The company also announced a quarterly dividend of $0.25 per share and provided optimistic guidance for the full year, projecting 12% sales growth and 26% adjusted EPS growth. Key product lines, including Artegraft, showed significant growth, particularly in international markets.
Read more →LMATLeMaitre Will Announce First Quarter 2026 Earnings Results on May 5, 2026
LeMaitre Vascular, Inc. will release its first quarter 2026 financial results on May 5, 2026, after market close. A conference call is scheduled for the same day at 5:00 PM EDT to discuss the results and company outlook. The event reflects the company's ongoing commitment to transparency and investor relations.
Read more →LMATLeMaitre to Present at the 25th Annual Needham Virtual Healthcare Conference
LeMaitre Vascular, Inc. announced its participation in the 25th Annual Needham Virtual Healthcare Conference scheduled for April 16, 2025. The presentation will be led by management, highlighting the company's commitment to addressing peripheral vascular disease. LeMaitre specializes in devices and services for vascular surgeons, catering to a significant global patient population.
Read more →LMATLeMaitre to Participate at Upcoming Investor Conferences in March 2026
LeMaitre Vascular, Inc. will participate in five investor conferences in March 2026, including notable events like the Leerink Partners Global Healthcare Conference and the Barclays Annual Global Healthcare Conference. Management will present and be available for one-on-one meetings, aiming to strengthen investor relations and showcase their vascular devices.
Read more →LMATLeMaitre to Participate at Upcoming Investor Conferences in March
LeMaitre Vascular, Inc. will participate in five investor conferences throughout March 2026, including the Leerink Partners and Barclays Annual Global Healthcare Conference. Management is scheduled to present and will be readily available for one-on-one meetings during these events. This engagement indicates the company's proactive approach in connecting with investors while emphasizing its role in treating peripheral vascular disease, a major global health issue.
Read more →LMAT▲ +24.4%on this newsshared move
LeMaitre Q4 2025 Financial Results
LeMaitre Vascular, Inc. reported strong Q4 2025 results with a 16% increase in sales and a 47% rise in operating income. The company announced a quarterly dividend increase of 25% and provided optimistic guidance for 2026, projecting $280 million in sales. Growth was driven by strong performance in grafts, valvulotomes, and carotid shunts across various regions.
Read more →LMATLeMaitre Q4 2025 Financial Results BURLINGTON, MA, February 25, 2026 - LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today
LeMaitre Vascular, Inc. reported strong Q4 2025 financial results, with sales driven by significant growth in key product categories. The company announced a 25% increase in its quarterly dividend and provided optimistic guidance for 2026, anticipating sales of $280 million and adjusted operating income growth. The results highlighted a gross margin increase and overall operational efficiency improvements. The outlook for the upcoming year appears robust, reflecting confidence in the company's strategic initiatives.
Read more →LMATLeMaitre Will Announce Fourth Quarter 2025 Earnings Results February 25, 2026
LeMaitre Vascular, Inc. has announced that it will release its fourth quarter 2025 financial results on February 25, 2026, after market close. A conference call is scheduled for the same day at 5:00 PM EST to discuss the results and company outlook. The call will be accessible to registered participants.
Read more →LMATLeMaitre to Participate in Upcoming Investor Conferences
LeMaitre Vascular, Inc. has announced its participation in three upcoming investor conferences. CFO Dorian LeBlanc will present at the Jefferies London Healthcare Conference and the Piper Sandler 37th Annual Healthcare Conference, while President David Roberts will present at the Wolfe Research 7th Annual Healthcare Conference. These events aim to enhance investor relations and showcase the company's offerings in peripheral vascular disease treatment.
Read more →LMATLeMaitre Q3 2025 Financial Results
LeMaitre Vascular, Inc. reported strong Q3 2025 financial results, with significant sales growth driven by grafts and shunts. The international launch of Artegraft contributed to a 33% increase in sales. The company announced a quarterly dividend of $0.20 per share and provided positive guidance for the remainder of the year. Adjusted gross margins improved due to higher selling prices and operational efficiencies.
Read more →LMATLeMaitre Q3 2025 Financial Results BURLINGTON, MA, November 6, 2025 - LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today
LeMaitre Vascular, Inc. reported strong Q3 2025 financial results with notable sales growth in its vascular devices. The company's adjusted gross margin increased to 70.8%, aided by rising average selling prices and greater manufacturing efficiencies. CEO George LeMaitre expressed optimism regarding the company's growth trajectory and highlighted the successful international launch of Artegraft. Additionally, the company announced a quarterly dividend of $0.20 per share, affirming its financial health.
Read more →About LeMaitre Vascular, Inc.
Headquarters63 SECOND AVENUE, BURLINGTON, MA, 01803
BIOPHARMAWATCH ELITE PLUS
Trade the next LMAT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime